Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naïve patients in China.

BACKGROUND:Hepatitis C is the second fastest growing infectious disease in China. The standard-of-care for chronic hepatitis C in China is Pegylated interferon plus ribavirin (PR), which is associated with tolerability and efficacy issues. An interferon- and ribavirin-free, all-oral regimen comprisi...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Yun Lu, Xiuze Jin, Cheng-A-Xin Duan, Feng Chang
Materialtyp: Artigo
Språk:Inglês
Publicerad: Public Library of Science (PLoS) 2018-01-01
Serie:PLoS ONE
Länkar:http://europepmc.org/articles/PMC5892899?pdf=render
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk